AU2019382168A1 - A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension - Google Patents
A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension Download PDFInfo
- Publication number
- AU2019382168A1 AU2019382168A1 AU2019382168A AU2019382168A AU2019382168A1 AU 2019382168 A1 AU2019382168 A1 AU 2019382168A1 AU 2019382168 A AU2019382168 A AU 2019382168A AU 2019382168 A AU2019382168 A AU 2019382168A AU 2019382168 A1 AU2019382168 A1 AU 2019382168A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- diazaspiro
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862768575P | 2018-11-16 | 2018-11-16 | |
| US62/768,575 | 2018-11-16 | ||
| PCT/IB2019/001224 WO2020099926A1 (en) | 2018-11-16 | 2019-11-15 | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019382168A1 true AU2019382168A1 (en) | 2021-06-03 |
Family
ID=69182543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019382168A Abandoned AU2019382168A1 (en) | 2018-11-16 | 2019-11-15 | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11413287B2 (https=) |
| EP (1) | EP3880203A1 (https=) |
| JP (2) | JP2022507533A (https=) |
| KR (1) | KR20210105343A (https=) |
| CN (1) | CN113242736A (https=) |
| AU (1) | AU2019382168A1 (https=) |
| CA (1) | CA3119909A1 (https=) |
| WO (1) | WO2020099926A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11413287B2 (en) | 2018-11-16 | 2022-08-16 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| WO2020128614A1 (en) * | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Method for treating interstital lung disease |
| MX2021009055A (es) | 2019-01-30 | 2021-10-22 | Altavant Sciences Gmbh | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. |
| AU2020244278A1 (en) * | 2019-03-15 | 2021-09-30 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
| WO2023062595A1 (en) * | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7875622B2 (en) | 2007-07-11 | 2011-01-25 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
| TW201245183A (en) * | 2010-11-05 | 2012-11-16 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid |
| UA119247C2 (uk) * | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| US9399741B2 (en) | 2013-10-09 | 2016-07-26 | Uop Llc | Methods and apparatuses for desulfurizing hydrocarbon streams |
| CA3119912A1 (en) * | 2018-11-14 | 2020-05-22 | Altavant Sciences Gmbh | A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin |
| US11413287B2 (en) | 2018-11-16 | 2022-08-16 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| WO2020128614A1 (en) * | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Method for treating interstital lung disease |
| WO2020128608A1 (en) | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension |
| MX2021009055A (es) * | 2019-01-30 | 2021-10-22 | Altavant Sciences Gmbh | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. |
| AU2020244278A1 (en) | 2019-03-15 | 2021-09-30 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
| CN115379825A (zh) | 2020-01-31 | 2022-11-22 | 阿尔塔万特科学公司 | 用rodatristat治疗肺动脉高压的剂量和方法 |
| US11937070B2 (en) | 2021-07-01 | 2024-03-19 | Tencent America LLC | Layered description of space of interest |
| WO2023079486A1 (en) | 2021-11-03 | 2023-05-11 | Altavant Sciences Gmbh | Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan |
-
2019
- 2019-11-15 US US16/685,165 patent/US11413287B2/en active Active
- 2019-11-15 CN CN201980083698.9A patent/CN113242736A/zh not_active Withdrawn
- 2019-11-15 AU AU2019382168A patent/AU2019382168A1/en not_active Abandoned
- 2019-11-15 WO PCT/IB2019/001224 patent/WO2020099926A1/en not_active Ceased
- 2019-11-15 KR KR1020217016464A patent/KR20210105343A/ko not_active Ceased
- 2019-11-15 CA CA3119909A patent/CA3119909A1/en active Pending
- 2019-11-15 EP EP19839404.1A patent/EP3880203A1/en not_active Withdrawn
- 2019-11-15 JP JP2021526561A patent/JP2022507533A/ja active Pending
-
2022
- 2022-07-18 US US17/813,173 patent/US11911382B2/en active Active
-
2023
- 2023-12-25 JP JP2023217954A patent/JP2024019691A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11911382B2 (en) | 2024-02-27 |
| US20230000866A1 (en) | 2023-01-05 |
| CN113242736A (zh) | 2021-08-10 |
| JP2022507533A (ja) | 2022-01-18 |
| US11413287B2 (en) | 2022-08-16 |
| KR20210105343A (ko) | 2021-08-26 |
| WO2020099926A1 (en) | 2020-05-22 |
| CA3119909A1 (en) | 2020-05-22 |
| JP2024019691A (ja) | 2024-02-09 |
| US20200155552A1 (en) | 2020-05-21 |
| EP3880203A1 (en) | 2021-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11911382B2 (en) | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
| US20240024316A1 (en) | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing | |
| US20220096475A1 (en) | Method for treating sarcoidosis-associated pulmonary hypertension | |
| US7834056B2 (en) | Pharmaceutical composition for gout | |
| EP3917531A1 (en) | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl | |
| US20080021083A1 (en) | 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance | |
| JPS61286326A (ja) | パ−キンソン病治療薬 | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| EP2853261B1 (en) | Agent for improving vesicourethral dyssynergia | |
| MX2010009917A (es) | Composicion de liberacion modificada que comprende doxofilina. | |
| KR100725263B1 (ko) | ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제 | |
| HK40065546A (en) | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing | |
| HK40058221A (en) | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
| CN114557992B (zh) | 一种复方药物组合物在制备治疗间质性肺炎药物中的应用 | |
| US20190381034A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases | |
| KR20180010475A (ko) | Trpc3의 억제제를 유효성분으로 포함하는 가려움증 치료용 약제학적 조성물 | |
| CN117243947A (zh) | 瑞香素及包含其的组合在制备糖尿病并发症药物中的应用 | |
| CN118871096A (zh) | 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物 | |
| CN112641765A (zh) | 丙泊酚的抗疲劳制药用途 | |
| DE102004040630A1 (de) | Kombinationstherapie mit Procain | |
| JP2000327571A (ja) | 抗かゆみ組成物 | |
| JP2005154367A (ja) | プロパフェノン含有神経因性疼痛の鎮痛剤 | |
| WO2005117853A1 (ja) | 高脂血症治療剤及び糖尿病治療剤 | |
| JP2005154368A (ja) | ジソピラミド含有神経因性疼痛の鎮痛剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |